// App-Quantinova.ai

P950 : COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE

Researchers

Presenter

  • Tobias S. Slrdahl

Principal Investigators

  • Frida Bugge Askeland

  • Margrete Sofie Stre Hanssen

  • Stine Marie Sundt-Hansen

  • Nils Tore Vethe

  • Henrik Hjorth-Hansen

  • Mona H. Fenstad

  • Anders Waage

  • yvind Hjertner

  • Fredrik Schjesvold

  • Anders Sundan

Medical Centers

  • Depart

  • Department of Immunology and Transfusion medicine, St.Olavs Hospital, Trondheim, Norway

  • Oslo Myeloma Center, Department of Hematology,Oslo University Hospital,Oslo,Norvegia

  • Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

  • Department of Pharmacology,Oslo University Hospital,Oslo,Noorwegen

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Oslo Myeloma Center, Department of Hematology,Oslo University Hospital,Oslo,Norvegia

  • Department of Immunology and Transfusion medicine, St.Olavs Hospital, Trondheim, Norway

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Department of Hematology,

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Pharmacology,Oslo University Hospital,Oslo,Noorwegen

  • Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

  • Department of Clinical and Molecular Medicin

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Oslo Myeloma Center, Department of Hematology,Oslo Universi

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Immunology and Transfusion Medicine,S

  • Department of Clinical and Molecular Medicine,Norwegian University of Science and Technology (NTNU),Trondheim,Norvège

  • Oslo Myeloma Center, Department of Hematology,Oslo University Hospital,Oslo,Norvegia

  • Department of Immunology and Transfusion medicine, St.Olavs Hospital, Trondheim, Norway

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Oslo Myeloma Center, Department of Hematology,Oslo University Hospital,Oslo,Norvegia

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Department of Immunology and Transfusion medicine, St.Olavs Hospital, Trondheim, Norway

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Ophthalmology,St. Olavs Hospital,Trondheim,Norwegen

  • Department of Surgery, St. Olavs Hospital, Trondheim, Norway

Locations

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved